Oral Supplement Containing Hydroxytyrosol and Punicalagin Improves Dyslipidemia in an Adult Population without Co-Adjuvant Treatment: A Randomized, Double-Blind, Controlled and Crossover Trial

Abstract

Hydroxytyrosol (HT) and punicalagin (PC) exert cardioprotective and antiatherosclerotic effects. This study evaluated the effect of an oral supplement containing HT and PC (SAx) on dyslipidemia in an adult population. A randomized, double-blind, controlled, crossover trial was conducted over a 20-week period. SAx significantly reduced the plasma levels of triglycerides (TG) in subjects with hypertriglyceridemia (≥150 mg/dL) (from 200.67 ± 51.38 to 155.33 ± 42.44 mg/dL; p < 0.05), while no such effects were observed in these subjects after the placebo. SAx also significantly decreased the plasma levels of low-density lipoprotein cholesterol (LDL-C) in subjects with high plasma levels of LDL-C (≥160 mg/dL) (from 179.13 ± 16.18 to 162.93 ± 27.05 mg/dL; p < 0.01), while no such positive effect was observed with the placebo. In addition, the placebo significantly reduced the plasma levels of high-density lipoprotein cholesterol (HDL-C) in the total population (from 64.49 ± 12.65 to 62.55 ± 11.57 mg/dL; p < 0.05), while SAx significantly increased the plasma levels of HDL-C in subjects with low plasma levels of HDL-C (<50 mg/dL) (from 44.25 ± 3.99 to 48.00 ± 7.27 mg/dL; p < 0.05). In conclusion, the supplement containing HT and PC exerted antiatherosclerotic and cardio-protective effects by considerably improving dyslipidemia in an adult population, without co-adjuvant treatment or adverse effects.

Association of hydroxytyrosol enriched olive oil with vascular function in chronic coronary disease

“…Malondialdehyde (MDA) was determined spectrophotometrically with a commercial kit (Oxford Biomedical Research, Rochester Hills, Mich, colorimetric assay for lipid peroxidation; measurement range 1–20 nmol/L) 15 . For MDA, the intra‐assay variability was 3.39%, respectively, and the inter‐assay 6 variability was 4.75%, respectively.…”

“…Additionally, HT reduced the serum interleukin‐6 (IL‐6) and C‐reactive protein (CRP) levels in mice 13 and had comparable action with aspirin in inhibiting of collagen‐induced platelet aggregation in whole blood 14 . Previous studies have shown a beneficial effect of olive oil extract supplements on endothelial function in subjects without known cardiovascular disease 15 . However, the effects of olive oil supplements on cardiovascular function in patients with chronic coronary artery syndrome (CCAS) have not been fully defined.…”

“…14 Previous studies have shown a beneficial effect of olive oil extract supplements on endothelial function in subjects without known cardiovascular disease. 15 However, the effects of olive oil supplements on cardiovascular function in patients with chronic coronary artery syndrome (CCAS) have not been fully defined.…”

Hydroxytyrosol: Its role in the prevention of cardiovascular diseases

“… [ 39 ] Eligible human patients (n = 30) Control group Extract group For 8 weeks 1 group consumed placebo and the other an extract from OO and AS EG decreased oxLDL levels and it improved oxLDL/LDL-col ratio. [ 40 ] Eligible human patients (n = 84) SAx supplement Placebo 3 capsules/day of the assigned product during 20 weeks separated into 8 weeks of treatment (supplement or placebo) by a washout period of 4 weeks. Supplementation decreased LDL and TG levels while it increases HDL levels.…”

“…The interventional product contained 3.3 mg of HT, 65 mg of PC and 331.7 mg of maltodextrin. Upon the intervention period, lipid profile improved notoriously by the decrease of LDL (p < 0.004), increase of HDL (p < 0.033) and decrease of TG (p < 0.017) [ 40 ] ( ClinicalTrials.gov , NCT02042742). Thus, the evidences presented in these clinical trials suggest that HT has a great pharmacological potential.…”